CYP19A1 and breast cancer: A higher disease control rate (DCR) was achieved in the TTC17Low arm of BC patients receiving rapamycin (P = 0.029), and stratified analysis demonstrated that in patients aged < 60 years (P = 0.006), with pathological grade 1 or 2 (P = 0.020), and a combination regimen of nonsteroidal aromatase inhibitor or exemestane (P = 0.001), low expression of TTC17 exhibited a more pronounced correlation with higher DCR (Fig. 6g–j).